Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 12/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3609366 | 1.00 | KDM1A (0.40) | KDM1ANPC1RXFP1DGAT2PTPN1 | |
| SCHEMBL13550257 | 0.88 | KDM1A (0.43) | KDM1ANPC1RXFP1DGAT2PTPN1 | |
| SCHEMBL13550258 | 0.88 | KDM1A (0.43) | KDM1ANPC1RXFP1DGAT2PTPN1 | |
| SCHEMBL8453294 | 0.84 | FAAH (0.47) | KDM1ANPC1RXFP1DGAT2PTPN1 | |
| SCHEMBL4605635 | 0.84 | FAAH (0.47) | KDM1ANPC1RXFP1DGAT2PTPN1 | |
| SCHEMBL8446370 | 0.84 | KDM1A (0.45) | KDM1ANPC1RXFP1PTPN1PTPN6 | |
| SCHEMBL8470015 | 0.83 | KDM1A (0.41) | KDM1ANPC1RXFP1DGAT2PTPN1 | |
| SCHEMBL4448506 | 0.83 | KDM1A (0.44) | KDM1ANPC1RXFP1DGAT2PTPN1 | |
| SCHEMBL16142526 | 0.83 | KDM1A (0.44) | KDM1ANPC1RXFP1DGAT2PTPN1 | |
| SCHEMBL4442037 | 0.83 | KDM1A (0.41) | KDM1ANPC1RXFP1DGAT2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121612-B1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2014-10-01 | — | — | EP | disclosed |
| EP-2121612-B1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2014-10-01 | — | — | EP | disclosed |
| US-8299102-B2 | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals | SANOFI (FR) | 2012-10-30 | — | — | US | disclosed |
| US-8299102-B2 | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals | SANOFI (FR) | 2012-10-30 | — | — | US | disclosed |
| US-20100016278-A1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | US | disclosed |
| US-20100016278-A1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | US | disclosed |
| EP-2121612-A1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008080511-A1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-07-10 | — | — | WO | disclosed |
| EP-1942104-A1 | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals | sanofi-aventis (FR) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016278-A1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | PTGIS, TBXAS1, EDNRA | KDM1A 1703/4885NPC1 3008/4885RXFP1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.